Celator's New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer
Source: Peter Byrne of The Life Sciences Report  (4/22/15)
Celator Pharmaceuticals Inc.'s remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes. More >

Ebola Vaccine Leaps Phase 1 Hurdle
Source: Stephen Petranek, The Daily Reckoning  (4/22/15)
"The Canadian National Microbiological Laboratory's new vaccine is licensed to NewLink Genetics, which in turn has licensed it to Merck. In two Phase 1 studies, the vaccine produced antibodies in volunteer subjects." More >

How to Make Money in Renewable Energy: NBF's Rupert Merer
Source: Peter Byrne of The Mining Report  (4/21/15)
As the political and financial pressures on fossil fuels mount, investors are starting to explore the renewable energy space with an eye toward reaping its potential. Rupert Merer analyzes that growing energy sector for National Bank Financial and tells The Mining Report why betting on the future of renewables is a prudent strategy for profit growth. More >

Gold Mining Stocks Get a Boost from M&A Activity
Source: Peter Krauth, Money Morning  (4/21/15)
"Investors in gold mining stocks have a great catalyst for profits right now: increased deal-making among gold mining companies." More >

Is This Where Investors Should Be Looking When Oil Recovers?
Source: James Stafford, Oilprice.com  (4/21/15)
The weeding out of the good deals from the bad deals has now begun to restore a balance to Saskatchewan, which maintains the promise of a highly attractive final frontier in which smart management makes all the difference. More >

Why Kal Kotecha Is Still Sticking with His New Year's Resolution
Source: The Gold Report Staff  (4/20/15)
Kal Kotecha, founder and editor of Junior Gold Report, says now is the time to be buying resource stocks, especially gold equities. He says the TSX Venture Exchange is the most decimated market in the world and the index will rebound to well beyond 1,000 in the next 12 to 24 months. In this interview with The Gold Report, he lists several gold and oil equities, some with near-term production narratives, others with longer-term potential.
More >

The Common Man: The Case for Copper and Zinc
Source: Robert Simpson, Resource Investing News  (4/20/15)
"The only bright spots, according to recent forecasts, appear to be in base metals such as copper and zinc." More >

How to Profit from Australia's Healthiest Biotechs: Wilson HTM's Shane Storey
Source: George S. Mack of The Life Sciences Report  (4/16/15)
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based Wilson HTM Investment Group, observes that as the market value of resource commodities declines, investors are diverting investment capital to healthcare stocks, especially in the medical technology sector. In this interview with The Life Sciences Report, Storey presents three names that don't come close to their long-term fair valuation potential. The upside, he believes, could be quite dramatic. More >

The Message from the Australian Front Is Uranium Is Looking More Attractive: Patersons' Simon Tonkin
Source: Peter Byrne of The Energy Report  (4/16/15)
Australia has a lock on a significant portion of the world's uranium reserves. Patersons Securities' Simon Tonkin is the go-to man for analyzing the Australian energy markets. In this interview with The Energy Report, Tonkin tells us how the uranium investment space works—and which junior explorers in Australia, Africa and North America look attractive as the price of yellowcake continues to stabilize. More >

M Partners' Derek Macpherson Found Three Resource Companies that Have Done the Impossible—Increased in Value 30% This Year
Source: Brian Sylvester of The Gold Report  (4/15/15)
If you don't like what people are saying about you, change the conversation. Derek Macpherson, an analyst with Toronto-based M Partners, covers three companies that are up over 30% year-to-date—and he believes those companies are performing because they got the market's attention by changing the conversation. In this interview with The Gold Report, Macpherson says companies that can change their narrative on the fly—and deliver—will inevitably perform. Macpherson covers some performers and others that he expects will perform in H2/15 and beyond. More >

Joe Reagor: Four Uranium Companies Poised to Profit from the Growth of Nuclear Power
Source: Kevin Michael Grace of The Mining Report  (4/14/15)
Nuclear power is enjoying a renaissance, and the world will soon need more uranium. Up to 50% more within a decade, says Joe Reagor of ROTH Capital. In this interview with The Mining Report, he explains that the share prices of uranium juniors remain low because the uranium spot price has not yet risen to reflect the increased demand just around the corner. This provides a great opportunity for canny, long-term investors, and Reagor identifies four companies that have the means to profit from the inevitable need for their product. More >

Christos Doulis Separates the Precious Metals Saints from the Sinners
Source: Brian Sylvester of The Gold Report  (4/13/15)
Christos Doulis, mining analyst with PI Financial, hopes for the best but plans for reality. The bear market in precious metals is well into its fourth year and could persist into 2016. In this interview with The Gold Report, Doulis says he remains hopeful that this is the year things take a positive turn, but in case we see more of the same, he recommends a few low-cost producers with saintly management teams that keep delivering on promises. More >

Biotech Winners Outnumber Losers in Q1/15
Source: EPVantage  (4/10/15)
"M&A continues to define this peer group, making inexpensive biotech assets as rare as hen's teeth." More >

Dundee's David Talbot Charges Ahead, Confident that Uranium Has a Bright Future
Source: Peter Byrne of The Energy Report  (4/9/15)
Smart energy investors pay attention when Dundee Capital Markets' David A. Talbot speaks. With decades of experience as a geologist and financial analyst, Talbot knows his game. He puts his muddy boots on the ground, always visiting a mine before recommending a buy. In a wide-ranging interview with The Energy Report, Talbot opens Dundee's basket of well-positioned uranium mining firms—all well-managed companies that will pump out riches as the uranium price stabilizes. More >

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Source: George S. Mack of The Life Sciences Report  (4/8/15)
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised patience. Jason Kolbert of New York City-based Maxim Group relishes finding early-stage, cutting-edge, small-cap names that he believes will change the paradigm of medical practice. In this interview with The Life Sciences Report, Kolbert shares a list of favorite biotechs developing products that will command premium pricing and sustained performance in the marketplace. More >

Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski
Source: Daniel Levy, The Life Sciences Report  (4/8/15)
Cancers are generally treated by destruction of cancer cells. Infectious diseases are generally treated by destruction of invading pathogens. If infected host cells are viewed as viable biological targets, new paradigms for development of anti-infective agents become apparent. In this interview with The Life Sciences Report, Alexander Zukiwski MD, CEO and CMO of Arno Therapeutics Inc., describes how onapristone and AR-42 for cancers, and AR-12 as an anti-infective agent, are positioned to move through clinical trials and boost investors' portfolios. More >

Soligenix Takes the Fast Track to Beat Inflammation, Cancer and Bio-Threats: Dr. Christopher Schaber
Source: Daniel Levy, The Life Sciences Report  (4/8/15)
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin. More >

Buy Precious Metal Equities Before the Bear Goes into Hibernation: Eric Muschinski
Source: Brian Sylvester of The Gold Report  (4/8/15)
Eric Muschinski, editor of the Chicago-based Gold Investment Letter, says that investing in a bear market is not about picking the absolute bottom—it's about accumulating your favorite companies regularly and averaging in at massive discounts. In this interview with The Gold Report, Muschinski lists some highly undervalued equities and tells investors to get more aggressive, especially this summer, when he believes the bear could go into hibernation. More >

Divestments: A Fundamental Tool in Biotech Growth Strategies
Source: Jeff Greene, EY  (4/8/15)
"The life sciences industry is undergoing a tectonic shift due to regulatory changes and a growing focus on patient outcomes. In response, leading companies are using divestments as a fundamental tool in their growth strategy." More >

Disruptive Stock Watcher Chris Berry Cautions Investors About the Real Potential of Deflation
Source: JT Long of The Mining Report  (4/7/15)
Where can investors turn when global quantitative easing and the Energizer Bunny of dollars is crushing commodity prices to within an inch of the junior miners' lives? In this interview with The Mining Report, Disruptive Discoveries Journal writer Chris Berry suggests dedicating yourself to understanding the technologies and paradigm shifts that can lower costs, and participating in the growing electric car and energy storage battery markets. He names some of the innovative companies that are finding new ways to separate the most valuable resources and enter the supply chain before it is too late. More >

Four Exploration and Development Companies Rick Mills Believes Will Thrive in Tough Times
Source: Kevin Michael Grace of The Gold Report  (4/6/15)
The four-year-long bear market in metals stocks has resulted in an historic opportunity for investors, says Rick Mills, the owner and host of Ahead of the Herd. In this interview with The Gold Report, he explains that gold and other metals must rise as supply falls, so that when the market finally turns, those companies that have continued to increase shareholder value will reward shareholders many-fold. And he highlights four companies poised to do just that. More >

A Commodities Market Rebound Investors Don't Want to Miss
Source: Peter Krauth, Money Morning  (4/3/15)
After four challenging years in the uranium space, there are finally signs suggesting this part of the commodities market is due for a recovery. . . More >

Why Biotech Investors Should Target the Takeouts: Cantor Fitzgerald's Irina Rivkind Koffler
Source: George S. Mack of The Life Sciences Report  (4/2/15)
Taking a page out of Big Pharma's playbook—looking for likely takeout candidates—is a profitable way to approach small-cap biotechs as potential investments, especially since large caps with shrinking pipelines have an unquenchable hunger for good new drugs and technologies, and the resources to track those drugs and technologies down. In this interview with The Life Sciences Report, Irina Rivkind Koffler of Cantor Fitzgerald brings two companies with takeout potential to the table. More >

How Sunesis Pharmaceuticals Can Inhibit Cancer While Enhancing Investments: CEO Daniel Swisher
Source: Daniel Levy, The Life Sciences Report  (4/2/15)
Cancers are among today's most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis expects to hit the mark both for patients and investors. More >

Chen Lin Sees Buying Opportunity of a Lifetime in Energy Stocks
Source: JT Long of The Energy Report  (4/2/15)
After correctly predicting $47/bbl oil last year, Chen Lin, author of the popular stock newsletter What Is Chen Buying? What Is Chen Selling?, is licking his stock-picking chops at the bargains now available in international oil plays and the ones that could materialize stateside if the artificial pressure on domestic oil created by a ban on exports is not lifted. In this interview with The Energy Report, he names three stocks that are the victims of global hysteria around plunging oil prices and blindness to local opportunities. More >